- Home
- AKBA vs RMR Comparison
AKBA vs RMR Comparison
Compare AKBA & RMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- RMR
- Stock Information
- Founded
- AKBA 2007
- RMR 1986
- Country
- AKBA United States
- RMR United States
- Employees
- AKBA N/A
- RMR N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- RMR Professional Services
- Sector
- AKBA Health Care
- RMR Consumer Discretionary
- Exchange
- AKBA Nasdaq
- RMR Nasdaq
- Market Cap
- AKBA 336.2M
- RMR 347.9M
- IPO Year
- AKBA 2014
- RMR N/A
- Fundamental
- Price
- AKBA $1.80
- RMR $17.94
- Analyst Decision
- AKBA Strong Buy
- RMR Buy
- Analyst Count
- AKBA 1
- RMR 2
- Target Price
- AKBA $7.50
- RMR $32.00
- AVG Volume (30 Days)
- AKBA 1.8M
- RMR 165.3K
- Earning Date
- AKBA 03-13-2025
- RMR 02-05-2025
- Dividend Yield
- AKBA N/A
- RMR 10.03%
- EPS Growth
- AKBA N/A
- RMR N/A
- EPS
- AKBA N/A
- RMR 0.97
- Revenue
- AKBA $169,879,000.00
- RMR $199,940,000.00
- Revenue This Year
- AKBA N/A
- RMR $371.91
- Revenue Next Year
- AKBA $19.31
- RMR $1.02
- P/E Ratio
- AKBA N/A
- RMR $18.40
- Revenue Growth
- AKBA N/A
- RMR N/A
- 52 Week Low
- AKBA $0.80
- RMR $17.75
- 52 Week High
- AKBA $2.48
- RMR $26.43
- Technical
- Relative Strength Index (RSI)
- AKBA 28.80
- RMR 30.31
- Support Level
- AKBA $2.07
- RMR $17.75
- Resistance Level
- AKBA $2.17
- RMR $19.24
- Average True Range (ATR)
- AKBA 0.08
- RMR 0.37
- MACD
- AKBA -0.05
- RMR 0.00
- Stochastic Oscillator
- AKBA 4.60
- RMR 12.75
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About RMR The RMR Group Inc.
The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.